| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Elderly, Children, Adult |
| State: | White Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier
| Items | Standards | Results | |
| Appearance | White or off-white crystalline powder | Complies | |
| Identification | By IR | Complies | |
| By HPLC | Complies | ||
| pH | 2.5~3.5 | 2.8 | |
| Loss on Drying | ≤ 1.00% | 0.30% | |
| Heavy Metals | ≤ 10ppm | Complies | |
| Residue on Ignition | ≤ 0.10% | 0.04% | |
| Relative Substance | Any single impurity: ≤0.50% | 0.15% | |
| Total Impurities: ≤1.00% | 0.48% | ||
| Purity(by HPLC) | ≥ 99.0% | 99.52% | |
| Assay (on the anhydrous basis) | 99.0%~101.5% | 99.58% | |
| Reference Standard | In-house Standard | ||
| Conclusion | The product complied to In-house standard. | ||
| Storage | Preserve in tight,light-resistant containers in a cool place | ||
Prasugrel (trade name Effient in the US and India, and Efient in the EU) is a pharmaceutical drug that acts as a platelet inhibitor and is used to prevent thrombosis (blood clotting). It was developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company.
Prasugrel was approved for use in Europe in February 2009, and in the US in July 2009, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).
Prasugrel is a new oral effective thienopyridine drug. Like clopidogrel, prasugrel is an inactive prodrug that is metabolically converted to an active metabolite by the cytochrome P450 enzyme system to irreversibly inhibit P2Y12 adenosine diphosphate receptors on platelets. Prasugrel is superior to clopidogrel, which explains why its pharmacokinetic properties are improved: prasugrel has a higher conversion of pro-drugs to active metabolites and higher bioavailability, so it is more effective. Rapidly and can reduce the difference in efficacy between individuals, to a greater extent reduce the incidence of major ischemic cardiovascular events.
| Product Name | CAS No. | Product Name | CAS No. |
| Lufenuron | 103055-07-8 | Toltrazuril | 69004-03-1 |
| Nitenpyram | 120738-89-8 | Praziquantel/Biltricide | 55268-74-1 |
| Fenbendazole | 43210-67-9 | Tetramisole Hcl | 5086-74-8 |
| Levamisole | 14769-73-4 | Ponazuril | 9004-4-2 |
| Diclazuril | 101831-37-2 | Florfenicol | 73231-34-2 |
| Ivermectin | 70288-86-7 | Enrofloxacin Hcl | 112732-17-9 |
| Albendazole | 54965-21-8 | Mebendazole | 31431-39-7 |
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}